A fixed-dose combination lozenge used for the symptomatic relief of sore throat and associated dry, non-productive cough. Amylmetacresol is a topical antiseptic and local anesthetic for the throat, while Dextromethorphan is a centrally-acting antitussive. It is a widely used OTC product in India for upper respiratory tract infections.
Adult: One lozenge to be dissolved slowly in the mouth every 2-3 hours. Maximum: 8 lozenges in 24 hours.
Note: Allow lozenge to dissolve slowly in the mouth. Do not chew or swallow whole. Do not consume food or drink immediately after taking the lozenge to prolong local effect. Use at regular intervals for symptomatic relief.
Amylmetacresol acts locally on the oropharyngeal mucosa to denature bacterial proteins and fungal cell membranes, providing antiseptic action. It also has a mild local anesthetic effect, soothing throat pain. Dextromethorphan is a sigma-1 receptor agonist and NMDA receptor antagonist that acts centrally on the cough center in the medulla oblongata, raising the threshold for cough reflex.
Pregnancy: Category C (US FDA). Animal studies show adverse effects. No adequate human studies. Use only if potential benefit justifies potential risk to the fetus. Avoid in first trimester.
Driving: May cause drowsiness or dizziness. Patients should not drive or operate machinery until their response is known.
| MAO Inhibitors (Phenelzine, Selegiline, Moclobemide) | Risk of severe serotonin syndrome, hyperpyrexia, death. | Contraindicated |
| SSRIs, SNRIs, Tricyclic Antidepressants | Increased risk of serotonin syndrome. | Major |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedation and CNS depression. | Major |
| CYP2D6 Inhibitors (Quinidine, Fluoxetine, Paroxetine) | Increased Dextromethorphan plasma levels, increased risk of side effects. | Moderate |
| Linezolid, Methylene Blue | Potential serotonin syndrome. | Major |
Same composition (Amylmetacresol (0.6mg) + Dextromethorphan Hydrobromide (5mg)), different brands: